US pauses tariff on Singapore patent drugs for exemption talks

The United States has reportedly postponed the implementation of 100 percent tariffs on patent medicines from Singapore, originally scheduled for October 1, according to a report by The Straits Times.

The delay will allow Singaporean pharmaceutical firms to negotiate possible exemptions with the US government, the report said.

According to Singapore's Minister of State for Foreign Affairs and Trade and Industry Gan Siow Huang, these companies are awaiting a response from the US government to determine if their capacity expansion plans meet the criteria for exemption.

Concurrently, the two countries are engaged in trade talks that include establishing preferential tariff arrangements for Singaporean drug exports.

While the US imposes a relatively low 10 percent baseline tariff on Singaporean products, these sector-specific tariffs pose a significant threat.

Singapore exports around nearly 4 billion Singaporean dollars' (HK$23.9 billion) worth of pharmaceutical products to the US, accounting for around 13 percent of its total exports to the country, the majority of which are patent-protected drugs.